| 重组人血管内皮抑制素注射液联合EP化疗、调强放疗对晚期非小细胞肺癌病人的影响 |
| |
| 引用本文： | 郑连喜,邓超,何平,屈敏.重组人血管内皮抑制素注射液联合EP化疗、调强放疗对晚期非小细胞肺癌病人的影响[J].蚌埠医学院学报,2020,45(8):1013-1016, 1019. |
| |
| 作者姓名： | 郑连喜 邓超 何平 屈敏 |
| |
| 作者单位： | 1.攀钢总医院 肿瘤科, 四川 攀枝花 6170002.重庆三峡中心医院 肿瘤科, 重庆 404000 |
| |
| 基金项目： | 四川省医学科研青年创新课题计划项目Q15012 |
| |
| 摘 要： | 目的探讨重组人血管内皮抑制素注射液联合EP化疗(依托泊苷+顺铂)及调强放疗在晚期非小细胞肺癌(NSCLC)治疗中的价值。方法按照随机数字表法将98例晚期NSCLC病人分为观察组与对照组，每组49例。对照组给予EP化疗+调强放疗，观察组在此基础上联合重组人血管内皮抑制素注射液治疗。对比2组治疗有效率、疾病控制率，治疗前后血清细胞角蛋白19片段21-1(CYFRA21-1)、糖类抗原50(CA50)以及生存质量；随访2年，统计对比2组生存情况。结果观察组治疗有效率63.27%，与对照组51.02%比较差异无统计学意义(P>0.05)，疾病控制率89.80%，高于对照组71.43%(P < 0.05)。治疗后观察组血清CYFRA21-1、CA50水平低于对照组(P < 0.01)。观察组生存质量改善率61.22%，高于对照组40.82%(P < 0.05)。观察组中位生存时间14个月，对照组中位生存时间11个月。观察组1年生存率59.57%、2年生存率34.04%与对照组的47.83%、26.09%比较差异无统计学意义(P>0.05)。结论EP化疗及调强放疗基础上联合重组人血管内皮抑制素注射液治疗晚期NSCLC，可有效提高疾病控制率、下调血清CYFRA21-1、CA50表达，且有利于改善病人生存质量，但该联合方案并不能显著提高病人生存率。
|
| 关 键 词： | 非小细胞肺癌 EP化疗方案 调强放疗 重组人血管内皮抑制素注射液 细胞角蛋白19片段21-1 糖类抗原50 |
| 收稿时间： | 2019-03-29 |
Effect of the recombinant human endostatin injection combined with EP chemotherapy and intensity-modulated radiotherapy in patients with advanced non-small cell lung cancer |
| |
| Affiliation: | 1.Department of Oncology, Panzhihua Iron and Steel General Hospital, Panzhihua Sichuan 6170002.Department of Oncology, The Central Hospital of Chongqing Three Gorges, Wanzhou Chongqing 404000, China |
| |
| Abstract: | ObjectiveTo investigate the value of recombinant human endostatin injection combined with EP chemotherapy(etoposide and cisplatin) and intensity-modulated radiotherapy in the treatment of advanced non-small cell lung cancer(NSCLC).MethodsNinety-eight patients with advanced NSCLC were divided into the observation group and control group according to the random number table method (49 cases in each group).The control group was treated with the EP chemotherapy combined with intensity-modulated radiotherapy, and the observation group was additionally treated with the recombinant human endostatin injection on the basis of control group.The response rate, disease control rate, serum levels of cytokeratin 19 fragment 21-1(CYFRA21-1), carbohydrate antigen 50(CA50) before and after treatment and quality of life were compared between two groups.All cases were followed up for 2 years, and the survival between two groups was compared.ResultsThe effective rates of treatment in observation group and control group were 63.27% and 51.02%, respectively, and the difference of which was not statistically significant(P>0.05).The disease control rate in observation group(89.80%) was higher than that in control group(71.43%)(P < 0.05).After treatment, the serum levels of CYFRA21-1 and CA50 in observation group were lower than those in control group(P < 0.01), and the improvement rate of survival quality in observation group(61.22%) was higher than that in control group(40.82%)(P < 0.05).The median survival time in observation group and control group were 14 months and 11 months, respectively.The 1-year and 2-year survival rates in observation group and control group were 59.57%, 34.04% and 47.83%, 26.09%, respectively, and the difference of which between two groups was not statistically significance(P>0.05).ConclusionsThe EP chemotherapy, intensity-modulated radiotherapy combined with recombinant human endostatin injection in the treatment of advanced NSCLC can effectively improve the disease control rate, down-regulate the serum levels of CYFRA21-1 and CA50, and improve the quality of life of patients, but it can not significantly improve the survival rate of patients. |
| |
| Keywords: | |
|
| 点击此处可从《蚌埠医学院学报》浏览原始摘要信息 |
|
点击此处可从《蚌埠医学院学报》下载全文 |
|
